Lung Cancer

Patients with NSCLC who are overweight or obese should discuss chemotherapy versus immunotherapy for frontline treatment, research showed.

Imfinzi has been approved as a presurgical treatment with platinum-based chemotherapy and postsurgical treatment alone in surgically removable NSCLC.

Patients with NSCLC taking five or more medications tended to have worse survival, highlighting the need for medication management, research showed.

Olomorasib plus Keytruda was proven to be safe and well tolerated for patients with KRAS G12C-mutant non-small cell lung cancer.

One expert explains how a break in TKI treatment could alleviate some toxicities, such as rash, for patients with non-small cell lung cancer.

From Patti Yasutake’s death from cancer to Olympic water polo player’s husband’s rare cancer diagnosis, here’s what’s happening in the oncology space this week.

The cancer vaccine, mRNA-4157, garnered immune responses of 30 weeks among some patients with melanoma and lung cancer, study results showed.

Patients with unresectable stage 3 non-small cell lung cancer treated with Tecentriq before and following chemoradiation may derive a survival benefit.

Certain patients with non-small cell lung cancer who are treatment-naive may benefit from receiving a biopsy regarding treatment decision-making.

Among patients with EGFR-mutated, advanced NSCLC, frontline treatment with Rybrevant plus Leclaza significantly prolonged progression-free survival.

I’ve been involved in the cancer community — in one way or another — since the 1990s, when my mother was facing breast cancer.

Treatment responses to Xalkori were not affected by PD-L1 expression in patients with advanced non-small cell lung cancer and ROS1 rearrangements.

A novel antibody-drug conjugate received an investigational new drug application for patients with gynecologic and lung cancers.

23andMe and 20 lung cancer advocacy organizations are working to improve lung cancer detection, risk reduction and care.

Sequencing the novel drug, THIO, with Libtayo tended to be tolerable in patients with non-small cell lung cancer, recent research showed.

A friend of mine is strong in her faith and is living well with a stage 4 cancer diagnosis. She is someone I look up to in these matters.

For some patients with early non-small cell lung cancer and lung scarring, stereotactic ablative radiotherapy may be a viable option, research has shown.

During summer 2024, there have been many changes made in the non-small cell lung cancer and small cell lung cancer spaces. Here are four top news stories.

When I started receiving chemotherapy for stage 3B lung cancer, I initially felt hopeless.

I used to think that having lung cancer canceled all of my life's plans, but I realized I shouldn't give it that much power.

Imdelltra has offered a new treatment option for patients with small cell lung cancer that “is not like anything we’ve ever seen before,” an expert said.

Dato-DXd did not improve survival in the overall population with non-small cell lung cancer but did boost outcomes in patients with non-squamous disease.

A Biologics License Application has been filed for the subcutaneous administration of Rybrevant for some patients with non-small cell lung cancer.

One expert explains why “the future of precision medicine” has arrived in lung cancer at the CURE® Educated Patient® Lung Cancer Summit.

Tumor characteristics are used to determine the best method of combining therapies with surgery for non-small cell lung cancer, according to a presentation at the CURE® Educated Patient® Lung Cancer Summit.

My reliable primary care physician was such an important asset in navigating multiple cancers.

Radiation plus targeted or immunotherapies could be beneficial for certain patients with lung cancer, and expert said at the CURE® Educated Patient® Lung Cancer Summit.

Patients with lung cancer may have personalized treatment options after biomarker testing, an expert said at the CURE® Educated Patient® Lung Cancer Summit.

Treatment for lung cancer has changed significantly with immunotherapy, an expert said during the CURE® Educated Patient® Lung Cancer Summit.

The Food and Drug Administration approved Augtyro for patients over the age of 12 with NTRK-positive solid tumors.